At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...

For some cases of cancer, the starting point of a new treatment is already inside the patient. Cell therapy provides another option for advanced blood cancers that have not responded to other drugs.

A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...

Tevogen Bio announced an agreement with CD 8 Technology Services to develop a turn-key facility aimed at enhancing its in-house capabilities for pre-clinical research and GMP cell therapy production.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS ...

Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts. CEO Ryan Saadi ...

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...

NETs promote macrophage expression of T-cell chemokines and subsequently facilitate cytotoxic CD8+ T cell infiltration and granzyme B production, which drives kidney fibrosis in obstructive ...